Role of caveolin-1 in the maintenance of blood-retinal barrier integrity
Caveolin-1 在维持血视网膜屏障完整性中的作用
基本信息
- 批准号:9563983
- 负责人:
- 金额:$ 36.03万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-12-01 至 2020-06-30
- 项目状态:已结题
- 来源:
- 关键词:AblationAddressAdverse effectsAge related macular degenerationAnti-inflammatoryBiological Response ModifiersBlindnessBlood VesselsBlood-Retinal BarrierCAV1 geneCardiovascular PhysiologyCaveolaeCellsComplexDevelopmentDiabetic RetinopathyDiseaseEye diseasesFunctional disorderGenesGlaucomaGoalsHomeostasisImmune signalingImmunologic ReceptorsInflammationInflammatoryInflammatory ResponseIonsIsoflavonesKnockout MiceLinkMaintenanceMediatingMembraneModelingNerve DegenerationNeurogliaPathologicPharmacologyPhysiologyPlayPreclinical TestingPrimary Open Angle GlaucomaProductionPropertyProteinsRegulationRetinaRetinalRetinal DegenerationRetinal DiseasesRiskRoleSignal TransductionSteroidsTLR4 geneTNF receptor-associated factor 3TNFRSF5 geneTestingTissuesToll-like receptorsTreatment EfficacyUbiquitinationautoimmune uveitisbasecaveolin 1cytokinedaidzeinimmune activationin vivoneurovascularneurovascular unitnew therapeutic targetnovelpathogenretinal damagetargeted treatmenttherapeutic evaluation
项目摘要
Project Summary/Abstract
Caveolin-1 (Cav-1), the signature protein of caveolae membrane domains, is linked to several ocular/retinal
diseases including primary open angle glaucoma, diabetic retinopathy, and autoimmune uveitis. We have
found that Cav-1 and caveolae play important roles in blood-retinal barrier (BRB) integrity, ion homeostasis,
and retinal function. More recently, we have found that Cav-1 promotes the activation of Toll-like Receptor-4
(TLR4) propagating TLR4-induced cytokine production and inflammatory BRB breakdown. As Cav-1 is
upregulated in several retinal inflammatory conditions, our results imply that local disruption of Cav-1 function
presents a viable therapy to suppress retinal inflammatory insults. Given that current steroid-based therapies
for retinal inflammatory disease are not completely effective and fraught with potentially severe side effects, we
hypothesize that Cav-1 and caveolae domains represent novel therapeutic targets to suppress retinal
inflammation resulting from pathogens as well as from endogenous damage that occurs during retinal
degenerative diseases. However, as Cav-1 plays several important roles in retinal homeostasis and
cardiovascular function, we must carefully evaluate the cell and tissue-intrinsic roles of this protein to
determine the potential of suppressing Cav-1 function locally in the retina, it is imperative to understand the
mechanisms for these complex cell-intrinsic properties. In this proposal we will use cell-specific Cav-1
knockout mice to test cell-intrinsic Cav-1 functions in the hope of validating Cav-1 as a new therapeutic target
for retinal inflammation, BRB breakdown, and neurodegeneration induced by inflammation. We will test a novel
mechanism whereby Cav-1 modulates the stability of TNF Receptor Associated Factor 3 (TRAF3) a
downstream signaling component of innate immune receptors such as TLR4. TRAF3 is abundantly expressed
in the retina but has yet to be rigorously studied as a local regulator of immune signaling. The goals of this
proposal are to determine the mechanism(s) by which Cav-1 modulates retinal inflammatory signaling, BRB
breakdown, and neurodegeneration induced by both pathogen- and damage-derived immune activation. We
will also examine the mechanism by which Cav-1 controls retinal TRAF3 levels. These goals have clear
项目摘要/摘要
小窝蛋白-1(Cav-1)是小窝膜结构域的标志性蛋白,与多种眼/视网膜相关
疾病包括原发性开角型青光眼、糖尿病视网膜病变和自身免疫性葡萄膜炎。我们有
发现Cav-1和Caveolae在血视网膜屏障(BRB)的完整性、离子稳态、
和视网膜功能。最近,我们发现Cav-1促进Toll样受体-4的激活
(TLR4)传播TLR4诱导的细胞因子的产生和炎性BRB的破坏。和CAV-1一样
我们的结果表明,在几种视网膜炎症条件下,Cav-1功能的局部中断
提出了一种可行的治疗方法来抑制视网膜炎症。鉴于目前以类固醇为基础的疗法
对于视网膜炎症性疾病并不是完全有效的,而且充满了潜在的严重副作用,我们
假设Cav-1和小凹结构域代表抑制视网膜的新治疗靶点
由病原体引起的炎症以及在视网膜期间发生的内源性损害
退行性疾病。然而,由于Cav-1在视网膜动态平衡和
心血管功能,我们必须仔细评估这种蛋白质在细胞和组织中的内在作用,以
确定视网膜局部抑制Cav-1功能的可能性,了解
这些复杂的细胞固有属性的机制。在本提案中,我们将使用细胞特异性Cav-1
基因敲除小鼠测试细胞固有的Cav-1功能,希望验证Cav-1作为新的治疗靶点
用于视网膜炎症、BRB分解,以及炎症引起的神经变性。我们将测试一部小说
Cav-1调节肿瘤坏死因子受体相关因子3(TRAF3)a稳定性的机制
天然免疫受体的下游信号成分,如TLR4。TRAF3基因大量表达
在视网膜中,但作为免疫信号的局部调节因子尚未得到严格的研究。这样做的目的是
建议确定Cav-1调节视网膜炎症信号的机制(S)
由病原体和损伤引发的免疫激活所导致的崩溃和神经变性。我们
还将研究Cav-1控制视网膜TRAF3水平的机制。这些目标有明确的
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MICHAEL H ELLIOTT其他文献
MICHAEL H ELLIOTT的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MICHAEL H ELLIOTT', 18)}}的其他基金
Caveolae-based mechanosensors for conventional outflow regulation
用于传统流出调节的基于小凹的机械传感器
- 批准号:
10186755 - 财政年份:2018
- 资助金额:
$ 36.03万 - 项目类别:
Caveolae-based mechanosensors for conventional outflow regulation
用于传统流出调节的基于小凹的机械传感器
- 批准号:
9596193 - 财政年份:2018
- 资助金额:
$ 36.03万 - 项目类别:
Role of Caveolin-1 in the Maintenance of Blood-retinal Barrier Integrity
Caveolin-1 在维持血视网膜屏障完整性中的作用
- 批准号:
8963726 - 财政年份:2009
- 资助金额:
$ 36.03万 - 项目类别:
Role of Caveolin-1 in the Maintenance of Blood-retinal Barrier Integrity
Caveolin-1 在维持血视网膜屏障完整性中的作用
- 批准号:
10683155 - 财政年份:2009
- 资助金额:
$ 36.03万 - 项目类别:
Role of Caveolin-1 in the Maintenance of Blood-retinal Barrier Integrity
Caveolin-1 在维持血视网膜屏障完整性中的作用
- 批准号:
10475582 - 财政年份:2009
- 资助金额:
$ 36.03万 - 项目类别:
Role of Caveolin-1 in the Maintenance of Blood-retinal Barrier Integrity
Caveolin-1 在维持血视网膜屏障完整性中的作用
- 批准号:
8197255 - 财政年份:2009
- 资助金额:
$ 36.03万 - 项目类别:
Role of Caveolin-1 in the Maintenance of Blood-retinal Barrier Integrity
Caveolin-1 在维持血视网膜屏障完整性中的作用
- 批准号:
7783730 - 财政年份:2009
- 资助金额:
$ 36.03万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 36.03万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 36.03万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 36.03万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 36.03万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 36.03万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 36.03万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 36.03万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 36.03万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 36.03万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 36.03万 - 项目类别:
Research Grant